<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684463</url>
  </required_header>
  <id_info>
    <org_study_id>P04935</org_study_id>
    <nct_id>NCT00684463</nct_id>
  </id_info>
  <brief_title>Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)</brief_title>
  <official_title>Study to Evaluate the Efficacy and Safety of Single IV Doses of Onicit速 (Palonosetron) 0.25 mg in the Prevention of Acute and Delayed Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in Colombia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of single IV doses of
      Onicit速 (Palonosetron) 0.25 mg in the prevention of acute and delayed nausea and vomiting
      associated with moderate and highly emetogenic chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2007</start_date>
  <completion_date type="Actual">February 22, 2008</completion_date>
  <primary_completion_date type="Actual">February 22, 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients having achieved complete response (CR), defined as no emetic episodes and no rescue medication.</measure>
    <time_frame>During 24 hours after administration of chemotherapy.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieved a CR and of those who achieved complete control</measure>
    <time_frame>Days 1 to 5 at different time intervals for each secondary outcome.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of emetic episodes</measure>
    <time_frame>Days 1 to 5 at different time intervals for each secondary outcome.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first emetic episode; time to administration and need for rescue therapy; and to treatment failure time to first emetic episode or administration of rescue medication</measure>
    <time_frame>Days 1 to 5 at different time intervals for each secondary outcome.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Neoplasms</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Palonosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.</description>
    <arm_group_label>Palonosetron</arm_group_label>
    <other_name>SCH 734291 - Onicit速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be 18 years of age or older.

          -  Histological or cytological confirmation of malignant disease.

          -  Karnofsky index &gt;= 50%

          -  Na誰ve to chemotherapy (First Cycle of chemotherapy IV with moderate or high emetic
             risk administered during Day 1 of the study, according to modification of the
             classification of Paul Hesketh's schema published on Annals of Oncology 17: 20-28,
             2006 (Appendix 3).

          -  Patients that voluntarily sign the consent form.

        Exclusion Criteria:

          -  Pregnancy or suspected.

          -  Patients during breast feeding.

          -  Inability to understand or cooperate with the study procedures.

          -  Received any investigational drugs within 30 days before study entry.

          -  Received any drug with potential anti-emetic efficacy within 24 hours prior to the
             beginning of the treatment

          -  Seizure disorders requiring anticonvulsant medication.

          -  Persistent vomiting due to any organic etiology.

          -  Experienced any vomiting, nausea or retching, in the 24 hours prior to chemotherapy.

          -  Any systemic disease different to base disease

          -  Known current or history of drug or alcohol abuse

          -  Gastric outlet or intestinal obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiemetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Snyopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

